Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke
ConditionAcute Ischemic Stroke
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorQianfoshan Hospital
About this trial
This study conducted a comprehensive evaluation of commonly used neuroprotective agents in acute ischemic stroke, assessing their real-world value across six dimensions: safety, efficacy, cost-effectiveness, innovativeness, appropriateness, and accessibility. Employing a prospective observational design, it primarily investigates the association of edaravone and dexrazoxane with clinical outcomes in patients with mild-to-moderate stroke, with subgroup analyses performed according to Trial of Org 10172 in Acute Stroke Treatment （TOAST ）classification.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
1: Age≥18
Disqualifiers
1: A head CT or MRI scan indicates the presence of intracranial hemorrhagic disease
Trial population
Patients with ischemic stroke
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Proportion of patients with Modified Rankin Scale（mRS ）scores of 0-1
Time frame
90 daysSecondary outcomes
1
Proportion of patients with mRS scores of 0-2
Time frame
30 days2
Percentage reduction in National Institutes of Health Stroke Scale （NIHSS ）score compared to pre-treatment
Time frame
90 days after medicationLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: